Sign in
CYAD Stock Price, Chart, Stats & News
Celyad Oncology S.A.
Save
14.24M
Market cap
–
Current P/E
–
Forward P/E
CYAD chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 93.55% |
Operating margin | -3149.46% |
Pretax margin | -3131.18% |
Net margin | -3131.18% |
Effective tax rate | – |
ROA | -35.77% |
ROE | -109.67% |
D/E | 0.17x |
Interest coverage ratio | – |
CYAD valuation
P/E | – |
P/S | 66.35x |
P/B | 2.68x |
P/CF | -1.11x |
P/FCF | -0.77x |
P/OCF | -1.11x |
PEG | -0.10x |
EV multiple | -3.22x |
About
Celyad Oncology S. A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing novel chimeric antigen receptor T (CAR-T) cell therapies aimed at combating various cancers. The company boasts several promising therapeutic candidates in clinical trials.
Similar securities
Based on sector and market capitalization
Report issue